Navigation Links
Baxa Corporation Introduces ExactaMix™ 1200 Automated Compounder for Sterile, Multi-Ingredient Solutions
Date:11/9/2010

ENGLEWOOD, Colo., Nov. 9, 2010 /PRNewswire/ -- Baxa Corporation, a leading provider of medical devices and systems that automate pharmacy operations, today introduced the ExactaMix 1200 Automated Compounding Device (ACD) for small- to mid-sized hospital pharmacies in need of an automated approach to compounding large-volume parenteral doses.  The entry-level 12-port compounder extends the market-proven Baxa ExactaMix Product Line and brings delivery precision and safe handling to pharmacies that want the compounding safety and efficiency that automation offers, but don't require the full range of the ExactaMix 2400 Compounder's capabilities.  The new ExactaMix 1200 will be exhibited next month at the 2010 American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting (MCM) & Exhibition.

The ExactaMix products automatically compound sterile doses, minimizing the risk of measurement errors, wrong drug selection, touch contamination and patient infection in the preparation of solutions for TPN, cardioplegia, dialysis and epidural delivery.  Capable of volumes as low as 0.2 mL, the new ExactaMix 1200 safely and accurately delivers both micro and macro ingredients. The ExactaMix 1200 and ExactaMix 2400 are the only ACDs with both volumetric delivery and gravimetric check, enabling pharmacists to ensure accuracy with both volume and fill data.

State-of-the-art Baxa compounding technology delivers final bag accuracies within +/- 4% with barcode ingredient verification, and pumps a typical three-liter nutrition bag in approximately 3.5 minutes -- nearly two times faster than industry average.  Its features improve compounding efficiency, enabling pharmacy professionals to focus on patient care with the confidence that safety, regulatory compliance and preparation accuracy goals are met.

"The ExactaMix 1200 dispels the myth that only large healthcare facilities and hospitals can take advantage of the safety and efficiency of proven, cutting-edge automated compounding technology," said Laura Zoerner, Senior Product Manager at Baxa Corporation.  "With the addition of the 12-port compounder, we now offer a wider range of solutions with globally recognized ExactaMix Technology. Now virtually any hospital can afford automated compounding for therapies such as TPN, cardioplegia and dialysis and epidural solutions to achieve both accuracy and speed -- while maintaining USP <797> compliance and delivering exactly right doses."

In its 45th year, the MCM takes place December 5 – 9, 2010 at the Anaheim Convention Center in Anaheim, California.  In addition to ExactaMix 1200, Baxa will showcase its extensive line of solutions that efficiently and safely deliver more than 450,000 doses each day, including its DoseEdge™ Pharmacy Workflow Management System.  Over 5 million doses have been processed by DoseEdge in US hospitals to date.  DoseEdge has prevented more than 100,000 preparation errors through barcode verification of every ingredient drug and best-practice compounding process management.  To view technical videos or download educational materials on FormularyPlus enhancements for DoseEdge, visit www.baxa.com/doseedge.

Baxa Corporation reliably and consistently enables pharmacists at more than 3,000 hospitals worldwide to safely prepare and administer intravenous therapies.  To learn more about the ExactaMix 1200, visit www.baxa.com/exactamix.  For additional information, to request a product brochure or download a free, educational white paper, visit www.baxa.com, call 800-567-2292 or email info@baxa.com.

About Baxa CorporationBaxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery.  Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications.  Key products include the Abacus® Order Entry and Calculation Software, the DoseEdge™ Pharmacy Workflow Manager, ExactaMed® Oral Syringes, ExactaMix™ Automated Compounding Devices, InFuse™ and MicroFuse® Syringe Infusers, Repeater™ Pharmacy Pumps, NeoThrive® Enteral Syringes, the PadLock®  Set Saver and the RapidFill™ Automated Syringe Filler; used worldwide in hospitals and healthcare facilities.  Its subsidiary FHT, Inc. produces the IntelliFill® i.v. automation.  Privately held, Baxa Corporation has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation in Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide.  Further information is available at www.baxa.com.Contact:Marian Robinson, Vice President, MarketingBaxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157Email:  marian.robinson@baxa.comPerrin McCormick or Brandie GerrishHart-Boillot: 781-893-0053Email: baxa@hartboillot.com
'/>"/>

SOURCE Baxa Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... the industry including definitions, classifications, applications and industry chain ... international market including development history, competitive landscape analysis, and ... ... industry spread across 105 pages providing 10 company profiles ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
(Date:3/24/2017)... -- Eli Lilly and Company (NYSE: LLY ... in its U.S. operations in 2017. The company,s ... research laboratories, manufacturing sites, and general and administrative ... for Lilly products, as well as its robust ... pain, diabetes and other unmet medical needs.  ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek ... services to families and business owners across eastern Michigan, is connecting with the ... struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just two days, Aqua ... micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the ... consumers (and counting) already backing the campaign. , “We are very grateful ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
Breaking Medicine News(10 mins):